Everything below concerns related substances. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
It also absorbed the separatist Caprivi African National Union (CANU), which was formed to combat South African rule in the Caprivi Strip. Outside the Soviet bloc, Egypt continued training SWALA personnel. By 1964 others were also being sent to Ghana, Algeria, the People's Republic of China, and North Korea for military instruction. In June of that year, SWAPO confirmed that it was irrevocably committed to the course of armed revolution. The formation of the Organisation of African Unity (OAU)'s Liberation Committee further strengthened SWAPO's international standing and ushered in an era of unprecedented political decline for SWANU. The Liberation Committee had obtained approximately £20,000 in obligatory contributions from OAU member states; these funds were offered to both South West African nationalist movements. However, as SWANU was unwilling to guarantee its share of the £20,000 would be used for armed struggle, this grant was awarded to SWAPO instead. The OAU subsequently withdrew recognition from SWANU, leaving SWAPO as the sole beneficiary of pan-African legitimacy. With OAU assistance, SWAPO opened diplomatic offices in Lusaka, Cairo, and London. SWANU belatedly embarked on a ten-year programme to raise its own guerrilla army. In September 1965, the first unit of six SWALA guerrillas, identified simply as "Group 1", departed the Kongwa refugee camp to infiltrate South West Africa. Group 1 trekked first into Angola, before crossing the border into the Caprivi Strip.
micronucleus The smaller of the two types of nuclei that occur in pairs in the cells of some ciliated protozoa. Whereas the larger macronucleus is polyploid, the micronucleus is diploid and generally transcriptionally inactive except for the purpose of sexual reproduction, where it has important functions during conjugation.
Best was elected a foreign member of the Royal Netherlands Academy of Arts and Sciences in 1946. He was elected a foreign honorary member of the American Academy of Arts and Sciences in 1948. He was elected to both the American Philosophical Society and the United States National Academy of Sciences in 1950. In 1967 he was made a Companion of the Order of Canada in recognition for "his contribution to medicine, particularly as co-discoverer of insulin." He was a commander of the Civil Division of the Order of the British Empire and was made a member of Order of the Companions of Honour in 1971 "for services to Medical Research". He was a fellow of the Royal Society of London, the Royal Society of Canada, and was the first Canadian to be elected into the Pontifical Academy of Sciences. As a recipient of the Order of Canada, he was awarded the Canadian version of the Queen Elizabeth II Silver Jubilee Medal in 1977. In 1994 he was inducted into the Canadian Medical Hall of Fame. In 2004, he was inducted into the National Inventors Hall of Fame. Dr. Charles Best Secondary School in Coquitlam, British Columbia, Dr. Charles Best Public School in Burlington, Ontario, and Charles H. Best Middle School in Toronto, Ontario, are named in his honour. His birthplace in Maine is listed on the United States National Register of Historic Places.
Sources: en.wikipedia.org
To Lore Alford Rogers In recognition of his quarter-century service in the advancement of knowledge, embracing important contributions in pure science as well as its applications to industry; and because he embodies in the highest degree their ideal of unselfish devotion and untiring loyalty, alike to his work and to his fellow workers--this volume is dedicated, with admiration and affection, by those who have been privileged to serve under his leadership. In the early 1930s Rogers was involved in research on cheese, including Swiss, cheddar, and Roquefort. He set off for the International Dairy Congress in Italy. In 1936 the Borden Company announced that it would provide cash awards and gold medals for "meritorious work in science as it is related to the dairy industry." Two recipients were selected for the first prizes: Lore A. Rogers of the USDA and Carl F. Huffman of Michigan State University. Rogers was praised for his numerous contributions to the field, noting "there is not a branch in our industry that has not felt the helping hand of his genius." In his casual, almost self-effacing style, but with serious reflection upon receiving the prize, Rogers took the opportunity to educate the next generation of researchers.
CCN family member 2, also known as Connective tissue growth factor (CTGF), is a protein encoded by the CCN2 gene in humans. CTGF is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins (see also CCN intercellular signaling protein). CTGF plays important roles in various biological processes, including cell adhesion, migration, proliferation, angiogenesis, skeletal development, and tissue wound repair, and is critically involved in fibrotic disease and several forms of cancer.
Penile ultrasonography with doppler can be used to examine the erect penis. Most cases of ED of organic causes are related to changes in blood flow in the corpora cavernosa, represented by occlusive artery disease (in which less blood is allowed to enter the penis), most often of atherosclerotic origin, or due to failure of the veno-occlusive mechanism (in which too much blood circulates back out of the penis). Before the Doppler sonogram, the penis should be examined in B mode, in order to identify possible tumors, fibrotic plaques, calcifications, or hematomas, and to evaluate the appearance of the cavernous arteries, which can be tortuous or atheromatous. Erection can be induced by injecting 10–20 μg of prostaglandin E1, with evaluations of the arterial flow every five minutes for 25–30 min (see image). The use of prostaglandin E1 is contraindicated in patients with predisposition to priapism (e.g., those with sickle cell anemia), anatomical deformity of the penis, or penile implants. Phentolamine (2 mg) is often added. Visual and tactile stimulation produces better results. Some authors recommend the use of sildenafil by mouth to replace the injectable drugs in cases of contraindications, although the efficacy of such medication is controversial. Before the injection of the chosen drug, the flow pattern is monophasic, with low systolic velocities and an absence of diastolic flow. After injection, systolic and diastolic peak velocities should increase, decreasing progressively with vein occlusion and becoming negative when the penis becomes rigid (see image below).
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.